Item Details
Indivior and Supernus Complete $3.4 Billion Pharmaceutical Merger
Indivior and Supernus Pharmaceuticals completed their approximately $3.4 billion merger on 2 November, creating a combined business focused on central nervous system medicines. The transaction highlights opportunities for pharmaceutical suppliers, healthcare consultants, clinical research providers and medical technology companies. HPC can support healthcare partnerships, supplier identification and pharmaceutical market research.
Get in Touch
We’ll get back to you shortly.